Barclays lowered the firm’s price target on Twist Bioscience (TWST) to $37 from $40 and keeps an Overweight rating on the shares. The firm says management’s description of being “commercially violent” continues to win market share. However, questions on Twist’s market opportunities remain, particularly in synthetic biology, the analyst tells investors in a research note.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TWST:
- Cathie Wood Cuts Stake in Pinterest Stock (PINS), Loads Up on Bitmine (BMNR) and Biotech Stocks
- Twist Bioscience Reports Record Revenue and Growth
- Twist Bioscience Achieves Record Revenue in Fiscal 2025
- Twist Bioscience: Balancing Near-Term Challenges with Medium-Term Growth Potential
- Midday Fly By: Walmart names new CEO, Merck acquires Cidara